What is Chimerix?
Headquartered in Durham, North Carolina, Chimerix is a specialized biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company maintains a diverse portfolio of nucleoside analogs, with a primary focus on preventing and treating serious viral infections. Its lead candidate, brincidofovir, represents a cornerstone of its clinical efforts, targeting viral threats in immunocompromised populations, including hematopoietic stem cell transplant recipients. Beyond its core antiviral programs, Chimerix leverages strategic partnerships with organizations such as BARDA to accelerate the development of medical countermeasures, positioning itself as a vital player in the global biopharma landscape.
How much funding has Chimerix raised?
Chimerix has raised a total of $237.9M across 8 funding rounds:
Series A
$1M
Series B
$3.1M
Unspecified
$36.1M
Series C
$11M
Series D
$23.1M
Other Financing Round
$16.1M
Other Financing Round
$45M
Stock Offering
$102.5M
Series A (2002): $1M with participation from Asset Management Company
Series B (2003): $3.1M led by Sanderling Ventures
Unspecified (2003): $36.1M supported by National Institutes of Health
Series C (2004): $11M featuring Sanderling Ventures
Series D (2007): $23.1M backed by Alta Partners, Sanderling Ventures, Canaan Partners, and Frazier Healthcare Partners
Other Financing Round (2009): $16.1M with participation from Sanderling Ventures, Alta Partners, and Canaan Partners
Other Financing Round (2011): $45M led by Morningside Group, Sanderling Ventures, Pappas Ventures, Alta Partners, Canaan Partners, New Leaf Venture Partners, and Frazier Healthcare Partners
Stock Issuance/Offering (2013): $102.5M, investors not publicly disclosed
Key Investors in Chimerix
Sanderling Ventures
A pioneering investment firm founded in 1979, specializing in building new biomedical companies through early-stage financing and active management.
Canaan Partners
An early-stage venture capital firm that invests in technology and healthcare companies, backing founders from seed through growth stages.
Alta Partners
A prominent venture capital firm specializing in healthcare and life sciences, dedicated to supporting entrepreneurs in building impactful companies since 1996.
What's next for Chimerix?
Looking ahead, Chimerix is poised to leverage its accumulated capital to advance its preclinical and clinical-stage assets, including CMX521 and CMX157. The firm's strategic roadmap emphasizes the rigorous execution of clinical trials and the expansion of its antiviral platform. By maintaining a disciplined approach to research and development, Chimerix aims to navigate the complexities of regulatory approval while maximizing the therapeutic potential of its nucleoside analog pipeline. Continued focus on high-impact medical indications will likely remain the primary driver for future growth and long-term value creation for stakeholders.
See full Chimerix company page
